Want To Control Drug Prices? Reject Price Controls

The past year has seen an epic confrontation pitting insurers and payers against drug companies. In the process, Sovaldi and, more recently, once-a-day interferon-free, Harvoni—Gilead Sciences Hepatitis C (HCV) treatments—have become the new poster children for pharmaceutical companies’ profiteering off the sick. Priced at $84,000 and $94,500, respectively, the two HCV drugs drew stinging rebukes from pharmaceutical benefit managers (PBMs), patient groups, and even the House Energy and Commerce Committee, in part because they were seen as breaking an unspoken rule.

Read More